Shalini Sharp's Insider Trades & SAST Disclosures
Shalini Sharp's most recent trade in BeiGene Ltd - ADR was a trade of 17,238 Share Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Shalini Sharp.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 17,238 | 17,238 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 8,151 | 8,151 (0%) | 0% | 0 | Ordinary Shares | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 9,638 | 36,783 | - | - | Phantom Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 2,100 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Sale of securities on an exchange or to another person at price $ 141.90 per share. | 17 May 2024 | 1,106 | 994 (0%) | 0% | 141.9 | 156,943 | Common Stock |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 10,086 | 25,594 | - | - | Phantom Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,290 | 4,290 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 2,100 | 2,100 | - | - | Restricted Stock Unit | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 7,520 | 7,520 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,444 | 9,414 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,640 | 14,935 | - | - | Phantom Stock | |
| Sutro Biopharma Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 3,688 | 3,688 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 2,546 | 4,970 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 9,061 | 9,061 | - | - | Phantom Stock | |
| Sutro Biopharma Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Precision Biosciences Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | EVP, Finance | Sale of securities on an exchange or to another person at price $ 87.99 per share. | 14 Oct 2020 | 375 | 97,812 (0%) | 0% | 88.0 | 32,996 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 7,188 | 98,187 (0%) | 0% | 88.4 | 635,275 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 7,188 | 15,812 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.55 per share. | 17 Aug 2020 | 7,188 | 105,375 (0%) | 0% | 67.5 | 485,549 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 3,669 | 15,312 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 3,669 | 98,187 (0%) | 0% | 88.4 | 324,266 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 17 Aug 2020 | 3,669 | 101,856 (0%) | 0% | 48.4 | 177,690 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.54 per share. | 17 Aug 2020 | 2,560 | 98,187 (0%) | 0% | 88.5 | 226,662 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 500 | 98,187 (0%) | 0% | 88.4 | 44,190 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.57 per share. | 17 Aug 2020 | 500 | 98,687 (0%) | 0% | 70.6 | 35,285 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 500 | 0 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.24 per share. | 17 Aug 2020 | 461 | 100,747 (0%) | 0% | 88.2 | 40,679 | Common Stock |
| Sutro Biopharma Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 03 Jun 2020 | 10,234 | 111,442 (0%) | 0% | 48.4 | 495,633 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 74.23 per share. | 03 Jun 2020 | 10,234 | 101,208 (0%) | 0% | 74.2 | 759,670 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2020 | 10,234 | 21,545 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2020 | 2,564 | 18,981 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 03 Jun 2020 | 2,564 | 103,772 (0%) | 0% | 48.4 | 124,175 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 74.01 per share. | 03 Jun 2020 | 2,564 | 101,208 (0%) | 0% | 74.0 | 189,762 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 01 Jun 2020 | 348 | 101,208 (0%) | 0% | 69.4 | 24,144 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 73.34 per share. | 18 May 2020 | 19,593 | 103,336 (0%) | 0% | 73.3 | 1,436,951 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.57 per share. | 18 May 2020 | 19,593 | 122,929 (0%) | 0% | 70.6 | 1,382,678 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2020 | 19,593 | 4,407 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2020 | 3,907 | 500 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 73.32 per share. | 18 May 2020 | 3,907 | 101,556 (0%) | 0% | 73.3 | 286,461 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.57 per share. | 18 May 2020 | 3,907 | 104,851 (0%) | 0% | 70.6 | 275,717 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 18 May 2020 | 3,221 | 104,165 (0%) | 0% | 48.4 | 155,993 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 73.32 per share. | 18 May 2020 | 3,221 | 100,944 (0%) | 0% | 73.3 | 236,164 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2020 | 3,221 | 31,779 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 73.29 per share. | 18 May 2020 | 2,392 | 100,944 (0%) | 0% | 73.3 | 175,310 | Common Stock |
| Precision Biosciences Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 41,038 | 41,038 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.26 per share. | 06 May 2020 | 248 | 103,336 (0%) | 0% | 66.3 | 16,432 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.57 per share. | 19 Apr 2020 | 248 | 103,584 (0%) | 0% | 58.6 | 14,525 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges